CHEK2 Positive: What This Moderate-Risk Gene Result Means for You and Your Family

CHEK2 (Checkpoint Kinase 2) is a gene that acts as a cell-cycle gatekeeper. When your cells are preparing to divide, the CHEK2 protein checks for DNA damage and signals the cell to pause and repair itself before dividing. When CHEK2 is mutated, this checkpoint is weakened: cells with unrepaired DNA damage may continue to divide, gradually accumulating changes that can lead to cancer.

CHEK2 is classified as a moderate-risk cancer gene. This means that while mutations in CHEK2 do increase cancer risk, the magnitude of that increase is lower than what is seen with high-risk genes like BRCA1 and BRCA2. Understanding this distinction is important because it directly affects what screening and management are recommended.

The most commonly studied CHEK2 variant is 1100delC, found in approximately 1 to 2 percent of people with Northern and Eastern European ancestry. Other variants exist, and your specific variant may influence your individual risk profile. For comprehensive gene-level information, see our CHEK2 gene guide.

CHEK2 mutations are associated with moderately elevated risks for several cancer types:

• Breast cancer (women): Lifetime risk of approximately 20 to 40 percent, depending on the specific variant and family history (general population: approximately 13 percent). The 1100delC variant is associated with a roughly two- to threefold increase over baseline risk.
• Colorectal cancer: Moderately increased risk, with some studies suggesting a lifetime risk of approximately 7 to 16 percent (general population: approximately 4 percent).
• Prostate cancer (men): Moderately elevated risk, particularly for the 1100delC variant. Enhanced screening may be discussed with your urologist.
• Kidney cancer: Some evidence of increased risk, though data is still accumulating.
• Thyroid cancer: A modest association has been reported in some studies.

These figures are population-level estimates. Your individual risk depends on your specific variant, family history, and other factors. Your genetic counselor will help contextualize these numbers for your personal situation. For a broader overview of all result categories, see our guide to understanding genetic test results.

One of the most important things to understand about a positive CHEK2 result is how it differs from a positive BRCA1 or BRCA2 result. The distinction affects nearly every aspect of clinical management:

• Risk magnitude: BRCA1 carriers face breast cancer risks of 45 to 72 percent; CHEK2 carriers face risks of 20 to 40 percent. The absolute risk difference is substantial.
• Preventive surgery: Risk-reducing mastectomy is a well-established option for BRCA carriers. For CHEK2 carriers, preventive surgery is generally not the standard recommendation, though it may be considered in the context of very strong family history. Enhanced screening is the primary strategy.
• Ovarian cancer: BRCA mutations carry significant ovarian cancer risk, leading to recommendations for risk-reducing salpingo-oophorectomy. CHEK2 is not associated with elevated ovarian cancer risk, and no ovarian-related interventions are recommended.
• Screening intensity: Both BRCA and CHEK2 carriers benefit from enhanced breast screening, but the starting ages and intervals may differ. CHEK2 carriers typically begin annual breast MRI at age 40 (versus age 25 for BRCA carriers).

The moderate-risk classification does not mean your result is unimportant. It means the management approach is different — focused on surveillance and early detection rather than risk-reducing surgery. Other moderate-risk genes such as ATM and PALB2 follow a similar management pattern. For an overview of how hereditary cancer screening eligibility is determined, see our hereditary cancer screening guide.

Based on current NCCN guidelines, the following screening recommendations apply to most CHEK2 carriers:

• Breast screening (women): Annual breast MRI starting at age 40 (or earlier if family history suggests higher risk). Annual mammography. Clinical breast examination every 6 to 12 months.
• Colorectal screening: Colonoscopy starting at age 40, or 10 years before the youngest colorectal cancer diagnosis in the family, whichever is earlier. Repeat every 5 years (or more frequently if polyps are found).
• Prostate screening (men): Discussion of enhanced prostate cancer screening with your urologist, potentially starting at age 40.
• General awareness: Report any new or unusual symptoms to your healthcare provider promptly. Maintain standard age-appropriate screening for other cancer types.

Your medical team will personalize these recommendations based on your specific variant, sex, age, and family history. Some carriers with particularly strong family histories may qualify for more intensive protocols. To learn more about working with a counselor, see our genetic counseling for hereditary cancer guide.

CHEK2 mutations follow autosomal dominant inheritance, meaning each of your first-degree relatives (parents, siblings, children) has a 50 percent chance of carrying the same variant. Cascade testing — targeted testing for your specific variant — is recommended for at-risk family members.

Because CHEK2 is a moderate-risk gene, some family members may wonder whether testing is worthwhile. The answer is generally yes: knowing their carrier status allows relatives to pursue enhanced screening and catch any cancers at the earliest possible stage, when outcomes are best. A negative cascade test result provides peace of mind and a return to general population screening guidelines. For general guidance on positive findings, see what happens after a positive genetic test.

Learn more about cascade testing for your family and how to approach these conversations.

Your genetic counseling session is an opportunity to understand your personal risk and develop a plan. Consider asking:

1. What is my specific CHEK2 variant, and how does it compare to the 1100delC variant in terms of risk?
2. Given my family history, should I begin breast screening earlier than age 40?
3. Is colonoscopy recommended for me, and at what age should I start?
4. Should I consider risk-reducing medications such as tamoxifen?
5. How should I approach cascade testing with my family members?
6. Are there clinical trials studying CHEK2-specific prevention or screening strategies?